1258 related articles for article (PubMed ID: 33155660)
61. Nerve growth factor suppresses the tumoral phenotype of human prolactinomas.
Missale C; Sigala S; Fiorentini C; Finardi A; Losa M; Giovanelli M; Spano P
Horm Res; 1997; 47(4-6):240-4. PubMed ID: 9167958
[TBL] [Abstract][Full Text] [Related]
62. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
63. Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Rondanin R; Simoni D; Maccesi M; Romagnoli R; Grimaudo S; Pipitone RM; Meli M; Cascio A; Tolomeo M
ChemMedChem; 2017 Aug; 12(15):1183-1190. PubMed ID: 28657677
[TBL] [Abstract][Full Text] [Related]
64. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.
Rondanin R; Simoni D; Romagnoli R; Baruchello R; Marchetti P; Costantini C; Fochi S; Padroni G; Grimaudo S; Pipitone RM; Meli M; Tolomeo M
Bioorg Med Chem Lett; 2014 Sep; 24(18):4568-4574. PubMed ID: 25131537
[TBL] [Abstract][Full Text] [Related]
66. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
67. Freeze-dried powder of daylily bud improves bromocriptine-induced lactation disorder in rats via JAK2/STAT5 pathway.
Guo S; Qin N; Wang X; Zuo Z; Li Q; Wang Y
J Ethnopharmacol; 2023 Sep; 313():116536. PubMed ID: 37120059
[TBL] [Abstract][Full Text] [Related]
68. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
69. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
Kanasaki H; Fukunaga K; Takahashi K; Miyazaki K; Miyamoto E
Biol Reprod; 2000 Jun; 62(6):1486-94. PubMed ID: 10819748
[TBL] [Abstract][Full Text] [Related]
70. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
71. Thymoquinone induces apoptosis of human renal carcinoma Caki-1 cells by inhibiting JAK2/STAT3 through pro-oxidant effect.
Chae IG; Song NY; Kim DH; Lee MY; Park JM; Chun KS
Food Chem Toxicol; 2020 May; 139():111253. PubMed ID: 32165235
[TBL] [Abstract][Full Text] [Related]
72. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation.
Fujinaka Y; Takane K; Yamashita H; Vasavada RC
J Biol Chem; 2007 Oct; 282(42):30707-17. PubMed ID: 17728251
[TBL] [Abstract][Full Text] [Related]
73. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
Paez-Pereda M; Giacomini D; Refojo D; Nagashima AC; Hopfner U; Grubler Y; Chervin A; Goldberg V; Goya R; Hentges ST; Low MJ; Holsboer F; Stalla GK; Arzt E
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1034-9. PubMed ID: 12552124
[TBL] [Abstract][Full Text] [Related]
74. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
75. Effects of pimozide and bromocriptine on anterior pituitary cell proliferation.
Stepień H; Wolaniuk A; Pawlikowski M
J Neural Transm; 1978; 42(3):239-44. PubMed ID: 690630
[TBL] [Abstract][Full Text] [Related]
76. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
77. Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway.
Ren Y; Tao J; Jiang Z; Guo D; Tang J
Life Sci; 2018 Sep; 209():267-273. PubMed ID: 30107167
[TBL] [Abstract][Full Text] [Related]
78. MicroRNA expression profile of bromocriptine-resistant prolactinomas.
Wu ZB; Li WQ; Lin SJ; Wang CD; Cai L; Lu JL; Chen YX; Su ZP; Shang HB; Yang WL; Zhao WG
Mol Cell Endocrinol; 2014 Sep; 395(1-2):10-8. PubMed ID: 25064468
[TBL] [Abstract][Full Text] [Related]
79. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
Barrera CM; Ruiz AE; Banks WA
Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
[TBL] [Abstract][Full Text] [Related]
80. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
